TARPLIN STRATEGIES LLC for GENENTECH, INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R. 3962, Affordable Health Care for America Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics. S. 1796, America's Healthy Future Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics. H.R. 3590, the Patient Protection and Affordable Care Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Medical/Disease Research/Clinical Labs MED
H.R. 3590 , the Patient Protection and Affordable Care Act of 2009 - authorization for comparative effectiveness research. S. 1213, the Patient-Centered Outcomes Research Act of 2009 - authorization for comparative effectiveness research. H.R. 3962, Affordable Health Care for America Act of 2009 - authorization for comparative effectiveness research. S. 1796, America's Healthy Future Act of 2009 - authorization for comparative effectiveness research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Health Issues HCR
H.R. 3962, Affordable Health Care for America Act of 2009 - government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics. S. 1679, the Affordable Health Choices Act of 2009 - government reimbursement for biotherapeutics, comparative effectiveness research, and legislative and regulatory issues involved in FDA approval of follow-on biologics. S. 1796, America's Healthy Future Act - Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research. H.R. 3590, the Patient Protection and Affordable Care Act of 2009 - Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Pharmacy PHA
H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics. H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics. H.R. 3962, Affordable Health Care for America Act - FDA approval of follow-on biologics and length of data exclusivity period. S. 1679, the Affordable Health Choices Act - FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program. S. 1796, America's Healthy Future Act of 2009 - Medicare and Medicaid reimbursement issues, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. S. 1232, the Pharmaceutical Market Access and Drug Safety Act, importation of prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.